Agnieszka Kotalczyk

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 311 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +11

Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA‐AF Phase III Registry

Valentina Bayer, Agnieszka Kotalczyk, Bory Kea et al. · Journal of the American Heart Association · 2022 · 36 citations · Full text

Medicine, Cardiology, Pharmacotherapy +15

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

Gregory Y.H. Lip, Agnieszka Kotalczyk, Christine Teutsch et al. · Clinical Research in Cardiology · 2022 · 34 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +13

4S‐AF scheme and ABC pathway guided management improves outcomes in atrial fibrillation patients

Yutao Guo, Jacopo Francesco Imberti, Agnieszka Kotalczyk et al. · European Journal of Clinical Investigation · 2022 · 32 citations · Full text

Medicine, Cardiology, Cardiovascular Pharmacotherapy +8

Effects of the Atrial Fibrillation Better Care Pathway on Outcomes Among Clinically Complex Chinese Patients With Atrial Fibrillation With Multimorbidity and Polypharmacy: A Report From the ChiOTEAF Registry

Agnieszka Kotalczyk, Yutao Guo, Maria Stefil et al. · Journal of the American Heart Association · 2022 · 31 citations · Full text

Pharmacy, Cardiology, Internal Medicine +14